• Malate as a Redox Lens in Tumor Immunometabolism

  2026-08-22

  Malate is more than a TCA-cycle metabolite: it is a practical perturbation and readout for connecting mitochondrial redox balance, PDHA1-linked metabolic rewiring, and macrophage immune function in translational cholangiocarcinoma research.

• PP 1: Src Family Tyrosine Kinase Inhibitor

  2026-08-21

  PP 1 is a Src family tyrosine kinase inhibitor used to study Lck, Fyn, Lyn, RET signaling, and T-cell activation modulation. Supplier-reported biochemical benchmarks show 5 nM inhibition of Lck and 6 nM inhibition of Fyn, while cellular and in vivo findings support use as a mechanistic research probe rather than as evidence of clinical cancer therapy.

• Annular Sector Microneedles for Glaucoma NAD+ Rescue

  2026-08-20

  This Biomaterials study combines Nmnat1 gene-loaded lipid nanoparticles with nicotinamide and an annular sector-shaped microneedle patch to target the trabecular meshwork in glaucoma. The approach improved mitochondrial-related pathology, reduced intraocular pressure, and alleviated fibrosis in cellular and dexamethasone-induced mouse models, while also defining important translational questions for localized ocular gene delivery.

• Central Control of Opioid Mechanical Hypersensitivity

  2026-08-20

  Yin et al. identify a lateral parabrachial–hypothalamic–spinal opioid circuit that controls morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The study provides a mechanistic framework for distinguishing central control of mechanical pain from better-established mechanisms of thermal opioid adaptation.

• CD38 CAR Binder Structure and Affinity Tuning

  2026-08-19

  Cheng and colleagues define how the CD38-targeting binders RP02 and 028 engage distinct structural regions and produce different effects on CD38 enzymatic activity. The study links epitope geometry and a rational 028R103G affinity adjustment to reduced CAR-T fratricide while preserving antitumor cytotoxicity, providing a structure-guided framework for CD38 therapeutic design.

• In Vitro mTOR Inhibition for Embryonic Dormancy

  2026-08-19

  This Nature Protocols study establishes noninvasive in vitro workflows for reversibly inducing a diapause-like dormant state in mouse blastocysts, human blastoids, and pluripotent stem cells through pharmacological mTOR inhibition. The framework improves experimental control and scalability for investigating embryonic dormancy while defining the readouts needed to distinguish stable developmental pausing from nonspecific loss of viability or proliferation.

• Cx43/NF-κB Control of AngII Macrophage Polarization

  2026-08-18

  The reference study shows that angiotensin II drives RAW264.7 macrophages toward a pro-inflammatory M1 phenotype through a connexin 43–NF-κB p65 signaling axis. Its pharmacological inhibitor experiments connect Cx43 activity with inflammatory marker expression and provide a mechanistic framework for studying macrophage behavior in cardiovascular inflammation.

• U0126 Workflows for MEK1/2 Inhibition

  2026-08-18

  U0126 provides a cell-permeable, non-ATP-competitive way to dissect MEK1/2 signaling, ERK suppression, adaptive resistance, and degradative-pathway phenotypes. This practical guide connects dose-response design with the HDAC8–PLCB1–DESC1–AKT resistance mechanism described in cancer models.

• Cryoablation, Tregs, and TGF-β in Lung Adenocarcinoma

  2026-08-17

  Lin et al. integrated single-cell profiling, prospective patient observations, bulk RNA sequencing, and cryoablation models to show how cryoablation reshapes regulatory T-cell activity in lung adenocarcinoma. The study connects reduced TGF-β1–Smad2/3 signaling with lower FOXP3 expression, impaired Treg conversion, and enhanced interferon-γ-associated antitumor immunity.

• Demethyleneberberine: From Mitochondria to Translation

  2026-08-17

  Demethyleneberberine (DMB) is emerging as a mechanistically rich natural product for translational inflammation, oncology, and neurobiology research. This article connects TLR4–mitochondrial signaling and NLRP3 inflammasome biology with practical model selection, formulation, and biomarker strategies, while defining the evidence boundaries between promising preclinical findings and clinical translation.

• Dehydroabietic Acid in Context: PPAR Assay Design

  2026-08-16

  Dehydroabietic acid can connect receptor pharmacology with whole-system metabolic reasoning. This guide uses new triacetin digestion findings to develop a more rigorous framework for dual PPAR-α/γ agonist assays, including controls, solvent handling, and translational limits.

• Carbapenemase Gene Transfer in CREC: Guangdong Study

  2026-08-15

  Chen et al. combine gene localization, antimicrobial susceptibility testing, conjugation, mobile-element analysis, and ERIC-PCR typing to investigate carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. The study shows that plasmid-associated blaNDM-1 was common and highly transferable, while strain typing indicates that both horizontal gene transfer and clonal dissemination may contribute to regional CREC persistence.

• Novel Allosteric PDK4 Inhibitors: Study Analysis

  2026-08-15

  The 2019 Journal of Medicinal Chemistry study describes a new allosteric PDK4 inhibitor series derived from an anthraquinone hit, with compound 8c reaching nanomolar in vitro potency. Its activity in glucose intolerance, allergic inflammation, and cancer-related cellular assays supports PDK4 as a mechanistically broad target, while also highlighting the need for further translational validation.

• GmMKK4–GmMPK6–GmERF113 Soybean Immunity Cascade

  2026-08-14

  The reference study defines a phosphorylation-dependent GmMKK4–GmMPK6–GmERF113 cascade that links Phytophthora sojae infection with soybean defense-gene activation. Its combination of genetic perturbation, interaction and kinase evidence, and downstream transcriptional analysis provides a framework for studying protein phosphorylation signaling in crop immunity.

• AZD0156: Translational Strategy for ATM Inhibition

  2026-08-13

  AZD0156 offers a precise way to interrogate ATM-dependent DNA damage signaling and design more informative combination studies. This thought-leadership guide connects selective pharmacology with target engagement, DNA double-strand break repair, checkpoint control modulation, biomarker strategy, and translational decision-making.

479 records 9/32 page Previous Next First page 上5页 678910 下5页 Last page